MUC1 and non-small cell lung carcinoma: In an ongoing phase I/II clinical trial conducted by PersonGen BioTherapeutics (Suzhou) Co., Ltd. (NCT02587689), anti-MUC1 CAR-T cells are being used to treat advanced refractory solid tumors, including NSCLC.